0.00
100.00%
-58.70
Mirati Therapeutics Inc stock is currently priced at $0.00, with a 24-hour trading volume of 0.
It has seen a -100.00% decreased in the last 24 hours and a -100.00% declined in the past month.
The chart indicates a potential bearish trend, as the stock is below the $58.74 pivot point. If it approaches the $58.05 support level, significant changes may occur.
Previous Close:
$58.70
Open:
$0
24h Volume:
0
Market Cap:
$4.12B
Revenue:
$38.19M
Net Income/Loss:
$-725.88M
P/E Ratio:
0.00
EPS:
-12.22
Net Cash Flow:
$-595.93M
1W Performance:
-100.00%
1M Performance:
-100.00%
6M Performance:
-100.00%
1Y Performance:
-100.00%
Mirati Therapeutics Inc Stock (MRTX) Company Profile
Name
Mirati Therapeutics Inc
Sector
Industry
Phone
858-332-3410
Address
9393 Towne Centre Drive, Suite 200, San Diego, CA
Mirati Therapeutics Inc Stock (MRTX) Upgrades & Downgrades
Date | Action | Analyst | Rating Change |
---|---|---|---|
Aug-10-23 | Upgrade | Citigroup | Neutral → Buy |
Aug-09-23 | Upgrade | B. Riley Securities | Neutral → Buy |
Aug-09-23 | Resumed | Piper Sandler | Overweight |
Jul-27-23 | Initiated | Scotiabank | Sector Underperform |
May-25-23 | Upgrade | Oppenheimer | Perform → Outperform |
Dec-14-22 | Initiated | Needham | Hold |
Dec-09-22 | Downgrade | Citigroup | Buy → Neutral |
Dec-08-22 | Downgrade | BMO Capital Markets | Outperform → Market Perform |
Dec-08-22 | Downgrade | JP Morgan | Overweight → Neutral |
Oct-28-22 | Initiated | B. Riley Securities | Neutral |
Sep-15-22 | Initiated | Piper Sandler | Overweight |
Jun-07-22 | Upgrade | JMP Securities | Mkt Perform → Mkt Outperform |
May-20-22 | Upgrade | Guggenheim | Neutral → Buy |
Feb-01-22 | Upgrade | BofA Securities | Underperform → Neutral |
Nov-19-21 | Initiated | BMO Capital Markets | Outperform |
Sep-23-21 | Initiated | Stifel | Buy |
Aug-26-21 | Initiated | Morgan Stanley | Equal-Weight |
Jun-04-21 | Upgrade | Citigroup | Neutral → Buy |
May-17-21 | Downgrade | Oppenheimer | Outperform → Perform |
May-10-21 | Upgrade | Jefferies | Hold → Buy |
Apr-26-21 | Resumed | Credit Suisse | Outperform |
Dec-08-20 | Initiated | Evercore ISI | Outperform |
Dec-08-20 | Initiated | JMP Securities | Mkt Perform |
Nov-17-20 | Downgrade | BofA Securities | Neutral → Underperform |
Nov-10-20 | Downgrade | Guggenheim | Buy → Neutral |
Nov-10-20 | Downgrade | Jefferies | Buy → Hold |
Nov-09-20 | Reiterated | H.C. Wainwright | Buy |
Sep-28-20 | Initiated | BofA Securities | Neutral |
Sep-18-20 | Downgrade | Citigroup | Buy → Neutral |
May-01-20 | Upgrade | JP Morgan | Neutral → Overweight |
Apr-16-20 | Initiated | Goldman | Buy |
Mar-12-20 | Upgrade | JP Morgan | Underweight → Neutral |
Jan-28-20 | Initiated | BMO Capital Markets | Market Perform |
Jan-27-20 | Initiated | BMO Capital Markets | Market Perform |
Sep-24-19 | Upgrade | Guggenheim | Neutral → Buy |
Sep-09-19 | Upgrade | Jefferies | Hold → Buy |
Aug-02-19 | Downgrade | JP Morgan | Neutral → Underweight |
Jul-18-19 | Initiated | Deutsche Bank | Hold |
Jun-19-19 | Downgrade | B. Riley FBR | Buy → Neutral |
Jun-07-19 | Downgrade | Guggenheim | Buy → Neutral |
Jun-05-19 | Reiterated | H.C. Wainwright | Buy |
View All
Mirati Therapeutics Inc Stock (MRTX) Latest News
Mirati (MRTX) Gets EU Nod for Krazati in KRAS-Mutated NSCLC
Zacks Investment Research
Bristol Myers (BMY) NSCLC Drug Application Gets EMA Validation
Zacks Investment Research
Bristol-Myers Squibb's Winning Formula: Dividends, M&A, And Innovation
Seeking Alpha
FDA Rejects Amgen's (AMGN) NDA Seeking Full Nod for Lumakras
Zacks Investment Research
Bristol Myers (BMY) to Buy Cancer Drug-Maker RayzeBio for $4.1B
Zacks Investment Research
Bristol Myers (BMY) to Buy Karuna Therapeutics for $14B
Zacks Investment Research
Mirati Therapeutics Inc Stock (MRTX) Financials Data
Mirati Therapeutics Inc (MRTX) Revenue 2024
MRTX reported a revenue (TTM) of $38.19 million for the quarter ending September 30, 2023, a +223.63% rise year-over-year.
Mirati Therapeutics Inc (MRTX) Net Income 2024
MRTX net income (TTM) was -$725.88 million for the quarter ending September 30, 2023, a +1.64% increase year-over-year.
Mirati Therapeutics Inc (MRTX) Cash Flow 2024
MRTX recorded a free cash flow (TTM) of -$595.93 million for the quarter ending September 30, 2023, a -1.62% decrease year-over-year.
Mirati Therapeutics Inc (MRTX) Earnings per Share 2024
MRTX earnings per share (TTM) was -$12.22 for the quarter ending September 30, 2023, a +8.74% growth year-over-year.
About Mirati Therapeutics Inc
Mirati Therapeutics, Inc., a clinical-stage oncology company, develops targeted therapeutics to address the genetic, epigenetic, and immunological promoters of cancer. The company is involved in developing sitravatinib, an oral spectrum-selective kinase inhibitor, which is in Phase II clinical for the treatment of solid tumor; and in Phase Ib clinical trial to treat non-small cell lung cancer (NCSLC) patients with CBL, chromosome 4q12, and RET genetic alterations, as well as mocetinostat, an orally administered spectrum-selective Class 1 histone deacetylase inhibitor that is in Phase II clinical trial in combination with durvalumab for the treatment of patients with NSCLC. Its preclinical development stage product candidate include KRAS G12C inhibitor program to address mutations and tumors. The company has a collaboration and license agreement with BeiGene, Ltd. to develop manufacture and commercialize sitravatinib. It also has collaboration with Astex Pharmaceuticals, Inc. and Merck & Co., Inc.; and Array BioPharma, Inc. to develop and commercialize products. Mirati Therapeutics, Inc. is headquartered in San Diego, California.
Cap:
|
Volume (24h):